Depression caused by genetic and environmental factors is a kind of complicated disease. Here, we find that Gsk3β is highly expressed and phosphorylated in the brain of chronic stress mouse. Inhibition of Gsk3β lead to decreased depression like symptoms which is manifested in open field test, tail-suspension test, forced-swim test and novelty suppressed feeding test. Besides, accompanied by activated Gsk3β, we find that β-catenin is attenuated, and its target genes Cyclin D1 and c-Myc are down-regulated. Meanwhile, it was also found that Gsk3β can inhibit the Erk-Creb-BDNF signaling. These results show that Gsk3β may promote the progression of depression. Therefore, target Gsk3β may be an effective therapeutic strategy.
BeurelE., GriecoS.F. and JopeR.S., Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases, Pharmacol. & Therapeut.148 (2015), 114–131. doi:10.1016/j.pharmthera.2014.11.016.
2.
BianY., YangL., WangZ., WangQ., ZengL. and XuG., Repeated three-hour maternal separation induces depression-like behavior and affects the expression of hippocampal plasticity-related proteins in C57BL/6N mice, Neural Plasticity2015 (2015), 627–837. doi:10.1155/2015/627837.
3.
BorosK., LacaudG. and KouskoffV., The transcription factor Mxd4 controls the proliferation of the first blood precursors at the onset of hematopoietic development in vitro, Exp. Hematol.39 (2011), 1090–1100. doi:10.1016/j.exphem.2011.07.007.
4.
ChenG., HuangL.D., JiangY.M. and ManjiH.K., The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3, J. Neurochem.72 (1999), 1327–1330. doi:10.1046/j.1471-4159.2000.0721327.x.
5.
Costemale-LacosteJ.F., GuillouxJ.P. and GaillardR., The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature, L'Encephale42 (2016), 156–164. doi:10.1016/j.encep.2016.02.003.
6.
DaveyC.G., YucelM. and AllenN.B., The emergence of depression in adolescence: Development of the prefrontal cortex and the representation of reward, Neurosci. Biobehav. Rev.32 (2008), 1–19. doi:10.1016/j.neubiorev.2007.04.016.
7.
FelgerJ.C., ColeS.W., PaceT.W., HuF., WoolwineB.J., DohoG.H., RaisonC.L. and MillerA.H., Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: Relationship with depression and fatigue, Psychol. Med.42 (2012), 1591–1603. doi:10.1017/S0033291711002868.
8.
HongistoV., SmedsN., BrechtS., HerdegenT., CourtneyM.J. and CoffeyE.T., Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3, Mol. Cell. Biol.23 (2003), 6027–6036. doi:10.1128/MCB.23.17.6027-6036.2003.
9.
HuangE.J. and ReichardtL.F., Neurotrophins: Roles in neuronal development and function, Annu. Rev. Neurosci.24 (2001), 677–736. doi:10.1146/annurev.neuro.24.1.677.
10.
HyeA., KerrF., ArcherN., FoyC., PoppeM., BrownR., HamiltonG., PowellJ., AndertonB. and LovestoneS., Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease, Neurosci. Lett.373 (2005), 1–4. doi:10.1016/j.neulet.2004.10.031.
11.
KrishnanV. and NestlerE.J., Animal models of depression: Molecular perspectives, Current Topics in Behav. Neurosci.7 (2011), 121–147. doi:10.1007/7854_2010_108.
12.
LindertJ., von EhrensteinO.S., GrashowR., GalG., BraehlerE. and WeisskopfM.G., Sexual and physical abuse in childhood is associated with depression and anxiety over the life course: Systematic review and meta-analysis, Int. J. Public Health59 (2014), 359–372. doi:10.1007/s00038-013-0519-5.
13.
LiuC., WangJ., XuS., AnS., TangS., HeJ., LiuY., LeeR.J. and WangD., Paecilomyces tenuipes extract prevents depression-like behaviors in chronic unpredictable mild stress-induced rat model via modulation of neurotransmitters, Mol. Med. Rep.16 (2017), 2172–2178. doi:10.3892/mmr.2017.6807.
14.
MandelliL. and SerrettiA., Gene environment interaction studies in depression and suicidal behavior: An update, Neurosci. Biobehav. Rev.37 (2013), 2375–2397. doi:10.1016/j.neubiorev.2013.07.011.
15.
MiyagawaK., TsujiM., IshiiD., TakedaK. and TakedaH., Prenatal stress induces vulnerability to stress together with the disruption of central serotonin neurons in mice, Behav. Brain Res.277 (2015), 228–236. doi:10.1016/j.bbr.2014.04.052.
16.
MuD. and HuangX., Anti-depression effects of electroacupuncture through up-regulating serum E2 and BDNF and expression of BDNF in hippocampus in chronic depression rats, J. Acupun. Tuina Sci.13 (2015), 141–145. doi:10.1007/s11726-015-0838-6.
17.
PhielC.J., WilsonC.A., LeeV.M. and KleinP.S., GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides, Nature423 (2003), 435–439. doi:10.1038/nature01640.
18.
RaisonC.L., BorisovA.S., WoolwineB.J., MassungB., VogtG. and MillerA.H., Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: Relationship with proinflammatory cytokines and behavior, Mol. Psychiatry15 (2010), 535–547. doi:10.1038/mp.2008.58.
19.
SchmidtP.J., Mood, depression, and reproductive hormones in the menopausal transition, Am. J. Med.118 (2005), 54–58. doi:10.1016/j.amjmed.2005.09.033.
20.
SeiraO. and Del RíoJ.A., Glycogen synthase kinase 3 beta (GSK3β) at the tip of neuronal development and regeneration, Mol. Neurobiol.49 (2014), 931–944. doi:10.1007/s12035-013-8571-y.
21.
StrekalovaT., MarkovaN., ShevtsovaE., ZubarevaO., BakhmetA., SteinbuschH.M., BachurinS. and LeschK.P., Individual differences in behavioural despair predict brain GSK-3beta expression in mice: The power of a modified swim test, Neural Plasticity2016 (2016), 5098591. doi:10.1155/2016/5098591.
22.
SzymanskaM., SuskaA., BudziszewskaB., Jaworska-FeilL., Basta-KaimA., LeskiewiczM., KuberaM., GergontA., KroczkaS., KacinskiM. and LasonW., Prenatal stress decreases glycogen synthase kinase-3 phosphorylation in the rat frontal cortex, Pharmacol. Rep.61 (2009), 612–620. doi:10.1016/S1734-1140(09)70113-6.
23.
TrivediM.H., RushA.J., WisniewskiS.R., NierenbergA.A., WardenD., RitzL., NorquistG., HowlandR.H., LebowitzB., McGrathP.J., Shores-WilsonK., BiggsM.M., BalasubramaniG.K., FavaM. and STAR*D Study Team, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice, Am. J. Psychiat.163 (2006), 28–40. doi:10.1176/appi.ajp.163.1.28.
24.
XiangQ., ChenW., RenM., WangJ., ZhangH., DavidY.B.D., ZhangL., ShangC. and ChenY., Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET, Clin. Cancer Res.20 (2014), 2959–2970. doi:10.1158/1078-0432.CCR-13-2620.
25.
YinF., BoverisA. and CadenasE., Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration, Antioxid. Redox Sign.20 (2014), 353–371. doi:10.1089/ars.2012.4774.
